A health economic analysis published in 2023 in the Journal of NeuroInterventional Surgery (JNIS) shows an innovative approach to the stroke care pathway reduced costs by an average of EUR 2,848 (~USD 3,120) per patient. The retrospective analysis looked at data from the controlled single-center ANGIOCAT clinical trial conducted at the Vall d’Hebron University Hospital Stroke Unit (Barcelona, Spain)11. Earlier results from this study demonstrated that a ‘Direct-to-Angio Suite’ (DTAS) pathway improves clinical outcomes for patients who have suffered a stroke.